Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
US FDA approves Axsome's drug for Alzheimer's-related agitation
02:10pm, Thursday, 30'th Apr 2026
The U.S. Food and Drug Administration has approved Axsome Therapeutics' drug to treat agitation in patients with Alzheimer's disease, the company said on Friday.
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
09:35am, Thursday, 30'th Apr 2026
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $1.07 per share a year ago.
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:01am, Monday, 27'th Apr 2026
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Knocks At $2 Billion Opportunity, Nears Buy Point
02:31pm, Thursday, 16'th Apr 2026
Axsome Therapeutics is nearing a buy point of 191.50.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of “Moderate Buy” by Brokerages
03:18am, Friday, 10'th Apr 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty research firms that are covering the firm, MarketBeat.com reports. T
Is This Healthcare Stock a Millionaire Maker?
05:48pm, Wednesday, 08'th Apr 2026
Axsome Therapeutics has performed well since its IPO. The company's current lineup and pipeline could drive growth for a while.
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
07:00am, Wednesday, 08'th Apr 2026
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a
SG Americas Securities LLC Acquires 5,584 Shares of Axsome Therapeutics, Inc. $AXSM
05:28am, Saturday, 04'th Apr 2026
SG Americas Securities LLC lifted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 46.2% during the fourth quarter, according to the company in its most recent Form 13F filing wit
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
05:24pm, Wednesday, 25'th Mar 2026
Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?
12:31pm, Wednesday, 25'th Mar 2026
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Critical Contrast: PTC Therapeutics (NASDAQ:PTCT) & Axsome Therapeutics (NASDAQ:AXSM)
02:56am, Monday, 23'rd Mar 2026
PTC Therapeutics (NASDAQ: PTCT - Get Free Report) and Axsome Therapeutics (NASDAQ: AXSM - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
11:37am, Wednesday, 18'th Mar 2026
Superstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter. The quarter-end position value was $6.84 million, representing a new holding in Axsome Therapeutics
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
12:41pm, Friday, 13'th Mar 2026
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
03:52am, Friday, 13'th Mar 2026
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
